This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 30, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it will host a conference call to discuss the exercise by
Purdue of its option to commercialize Intermezzo® (zolpidem tartrate) sublingual tablet C-IV in
the United States.
Conference Call InformationDate:
Thursday, December 1, 2011Time:
8:30 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at
www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until
December 31, 2011.
A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business
December 9, 2011. The replay telephone numbers are 855-859-2056 (U.S.) and 404-537-3406 (International), replay passcode: 32092646.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Transcept and
Purdue have entered into a collaboration agreement for the development and commercialization of Intermezzo in
the United States.
Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, to determine its effectiveness and safety when used as augmentation treatment in patients with obsessive-compulsive disorder who have not adequately responded to first-line pharmacotherapy. For further information, please visit the Transcept website at